Cited 9 times in
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.date.accessioned | 2022-09-02T01:05:04Z | - |
dc.date.available | 2022-09-02T01:05:04Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 0171-5216 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/189910 | - |
dc.description.abstract | Purpose Although immune-checkpoint inhibitors (ICIs) have emerged as therapeutic options for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC), concerns have been raised on exceptional acceleration of tumor growth during treatment with ICIs, a condition described as hyperprogressive disease (HPD). This study examined the incidence, potential predictors, and clinical impact of HPD in R/M-HNSCC. Methods We retrospectively collected data of patients with R/M-HNSCC treated with ICIs between January 2013 and June 2018 from 11 medical centers in Korea. HPD was defined as tumor growth kinetics ratio (TGKr) > 2, which was calculated by comparing TGK on ICIs with that before treatment with ICIs. Results Of 125 patients, 68 (54.4%) obtained progressive disease as their best responses (progressors). HPD was identified in 18 (26.5% of progressors, 14.4% of total) patients. Relatively younger age, primary tumor of oral cavity, and previous locoregional irradiation were significant predictors of HPD according to multivariable analysis (p = 0.040, 0.027, and 0.015, respectively). Compared to patients without HPD, patients with HPD had significantly shorter median progression-free survival (PFS) (1.2 vs. 3.4 months,p < 0.001) and overall survival (OS) (3.4 vs. 10.7 months,p = 0.047). However, interestingly, HPD did not significantly affect the therapeutic benefit of post-ICIs chemotherapy. Conclusions Younger patients with oral cavity cancer or prior treatment with locoregional radiotherapy could be regarded potential risk groups for HPD in patients with R/M-HNSCC treated with ICIs. Although HPD could consistently predict poorer survival outcomes, patients who experienced HPD with ICIs should not be excluded from the subsequent salvage chemotherapy treatments. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English, German | - |
dc.publisher | Springer-Verlag | - |
dc.relation.isPartOf | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Cell Proliferation / drug effects | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immune Checkpoint Inhibitors / administration & dosage* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mouth / drug effects* | - |
dc.subject.MESH | Mouth / pathology | - |
dc.subject.MESH | Neoplasm Recurrence, Local / drug therapy* | - |
dc.subject.MESH | Neoplasm Recurrence, Local / immunology | - |
dc.subject.MESH | Neoplasm Recurrence, Local / pathology | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Republic of Korea / epidemiology | - |
dc.subject.MESH | Squamous Cell Carcinoma of Head and Neck / drug therapy* | - |
dc.subject.MESH | Squamous Cell Carcinoma of Head and Neck / epidemiology | - |
dc.subject.MESH | Squamous Cell Carcinoma of Head and Neck / immunology | - |
dc.subject.MESH | Squamous Cell Carcinoma of Head and Neck / pathology | - |
dc.title | Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ji Hyun Park | - |
dc.contributor.googleauthor | Sang Hoon Chun | - |
dc.contributor.googleauthor | Yun-Gyoo Lee | - |
dc.contributor.googleauthor | Hyun Chang | - |
dc.contributor.googleauthor | Keun-Wook Lee | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Seong Hoon Shin | - |
dc.contributor.googleauthor | Ho Jung An | - |
dc.contributor.googleauthor | Kyoung Eun Lee | - |
dc.contributor.googleauthor | In Gyu Hwang | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.contributor.googleauthor | Sung-Bae Kim | - |
dc.contributor.googleauthor | Bhumsuk Keam | - |
dc.identifier.doi | 10.1007/s00432-020-03316-5 | - |
dc.contributor.localId | A01166 | - |
dc.relation.journalcode | J01283 | - |
dc.identifier.eissn | 1432-1335 | - |
dc.identifier.pmid | 32671504 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s00432-020-03316-5 | - |
dc.subject.keyword | Hyperprogressive disease | - |
dc.subject.keyword | Immune-checkpoint inhibitors | - |
dc.subject.keyword | Prognostic | - |
dc.subject.keyword | Impact | - |
dc.subject.keyword | Recurrent and | - |
dc.subject.keyword | or metastatic | - |
dc.subject.keyword | Head and neck squamous carcinoma | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.citation.volume | 146 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 3359 | - |
dc.citation.endPage | 3369 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, Vol.146(12) : 3359-3369, 2020-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.